Business Wire

Mary Kay Inc. Caps Off Landmark Scientific Credentialing Year at 73rd Society of Cosmetic Chemists Meeting

20.12.2019 17:00:00 EET | Business Wire | Press release

Share

In 2019, Mary Kay Inc. continued its decades-long commitment to skin science research by revealing the results of multiple groundbreaking studies and fostering academic discussion with industry peers at scientific symposiums around the globe. Most recently, Mary Kay was in New York City for the 73rd Society of Cosmetic Chemists Meeting, where the brand sponsored, collaborated, and explored applications of skin microbiome with leading experts in the field.

“New research suggests that microbes play an important role in overall skin health, and as leading skincare innovators, Mary Kay is heavily invested in further exploration of their impact,” said Dr. Lucy Gildea, Chief Scientific Officer at Mary Kay. “We have a commitment to take an active role in the beauty and scientific communities through participation in global dermatological conferences like the Society of Cosmetic Chemists Meeting, where we can share and learn from other scientific experts to help us develop more effective products.”

The Society of Cosmetic Chemists Meeting convenes over 1,300 attendees from some of the top cosmetic and personal care brands and manufacturers. Participants are encouraged to engage with speakers presenting the latest research and innovations of interest to cosmetic scientists, exchange ideas with peers, and reconnect with colleagues from around the globe.

Mary Kay sponsored the educational session at the meeting, including topics Quorum Quenching: the New Way to Keep Microbiome Under Control, Exploring New Applications in Personal Care: Balancing our Skin Microbiota, Global Microbiome Effects, and Temporal Variation of the Facial Skin Microbiome.

Additional 2019 Scientific Research and Credentialing

The 73rd Society of Chemists Meeting is the latest event in a series of Mary Kay presentations with the scientific and academic communities that reinforce the brand’s longstanding commitment to advancing skin health research and development. Every year, Mary Kay conducts hundreds of thousands of scientific tests on products and ingredients to ensure the highest standards of safety, quality and performance. Mary Kay holds more than 1,500 patents for products, technologies and packaging designs in its global portfolio. Recently, the company announced the opening of a more than $100 million state-of-the-art manufacturing and R&D facility in Lewisville, Texas.

In 2019, Mary Kay focused on three pillars in its commitment to skin health, including pollution; skin barrier health and sensitive skin; and the understanding of skin aging and strategies to intervene:

Pollution and Skin Health

  • May: Mary Kay sponsored an exclusive symposium on the impact of pollution on skin health in the Latin America region at the prestigious Reunión Anual de Dermatólogos Latinoamericanos (RADLA) in Buenos Aires, Argentina. Dr. Gildea moderated this symposium with 3 expert Brazilian dermatologists sharing research on the impact of air pollution on skin. It was concluded that antioxidants would be a viable way to counteract the negative effects of pollution on skin. Fortunately, Mary Kay also presented findings on an antioxidant complex that can help delay the premature signs of aging related to the damaging effects of air pollution.
  • June: Mary Kay the 24th World Congress of Dermatology in Milan, Italy. Mary Kay sponsored a Questions and Answers session with 2 dermatology experts on the impact of environmental stressors in Europe on skin. Dr. Michelle Hines, Global Upstream Research & Technology at Mary Kay hosted this event featuring two renowned Europe skin experts:
    • Jean Krutmann, M.D., Professor & Director at Leibniz Research Institute for Environmental Medicine – Dusseldorf, Germany.
    • Stefanie Williams, M.D., Dermatologist & Medical Director at EUDELO – London, United Kingdom.
  • June: At the 5th Future of Formulations in Cosmetics Summit in Dusseldorf, Germany, Dr. Hines revealed Mary Kay’s ongoing research on an antioxidant complex that helps delay the onset of premature signs of aging related to the damaging effects of diesel exhaust particles (DEP) on skin cells. The breakthrough technology, found in the Mary Kay® TimeWise® Miracle Set 3D skin care line, provides a powerful free-radical fighting regimen with an exclusive, patent-pending, three-dimensional approach to skin aging.

Skin Barrier Health and Sensitive Skin

  • March: At the 20th World Dermatology Congress in Singapore, David Gan, Senior Principal Scientist at Mary Kay Inc., presented some new insights in evaluating and understanding facial redness. Based on this work, Mary Kay scientists identified skincare technology that helps reduce the production of pro-inflammatory proteins and enzymes in the skin and developed a cosmetic formulation containing these ingredients to effectively address facial redness using unique clinical measures.
  • August: Mary Kay China’s Sr. Manager for Medical Affairs, Dr. Jenny Jiang, shared some strategies from Mary Kay research to improve the skin barrier function and facial redness at the Annual Meeting of the Dermatology Committee organized by the Chinese Association of Integrative Medicine in Lanzhou, Gansu Province, China. These findings may provide important insights to understanding sensitive skin.
  • November: Mary Kay was a symposium sponsor at the 44th annual meeting of The Japanese Society of Investigative Dermatology (JSID) in Aomori, Japan. Dr. Gildea moderated an educational symposium exploring environmental protection strategies against skin aging in Asians, protein response to skin inflammation and skin barrier defects. The panel featured three renowned dermatologists:
    • Dr. Akimichi Morita, MD Ph.D., Department of Geriatric and Environmental Dermatology at Nagoya City University Graduate School of Medical Sciences
    • Dr. Sang Eun Lee, MD Ph.D., Department of Dermatology, Gangnam Severance Hospital, Cutaneous Biology Research Institute, Yonsei University College of Medicine in Seoul, Korea
    • Dr. Gyohei Egawa, MD Ph.D., Department of Dermatology, Kyoto University Graduate School of Medicine

Understanding of Skin Aging and Skin Health and Strategies to Intervene

  • March: At the Skin of Color Society Symposium in Washington. D.C., Dr. Shoná Burkes-Henderson, Associate Principal Scientist, Clinical Research, revealed new research on navy bean extract and its ability to regulate melanogenesis, leading to an improvement in uneven skin tone and facial hyperpigmentation. Dr. Burkes-Henderson also presented a new approach to help improve facial erythema, or redness, at the American Academy of Dermatology Annual Meeting.
  • May: Mary Kay Associate Principal Scientist Dr. Tiffany Carle attended 77th Annual Meeting of the Society for Investigative Dermatology in Chicago, where she presented new data from analyzing the effects of a serum containing five botanical fruit extracts known to be rich in vitamin C on skin appearance. As part of this study, Mary Kay researchers treated artificial skin tissue with this serum and utilized a genomic approach to understand how the serum affected the skin.
  • June: Mary Kay sponsored the University of the Philippines Medical Alumni Society of America (UPMASA) 34th Annual Grand Convention (AGC) in Dallas. The conference convened more than 500 doctors from the U.S. and the Philippines to discuss topics ranging from dermatology to orthopedics and neurology.
  • September: Mary Kay shared its latest research targeting the causes and underlying mechanisms of slackened skin at the 49th Annual Meeting of the European Society for Dermatological Research (ESDR) held in Bordeaux, France. Dr. Michelle Hines shared data on technology that targeted slackened skin leading to improvement in skin clinical measures.
  • September: Mary Kay presented findings on research experiments that demonstrated how sunscreen viscosity, a property that effects application to skin, can be adjusted using processing parameters at the 2019 Sunscreen Symposium presented by the Florida chapter of the Society of Cosmetic Chemists in Lake Buena Vista, Florida.

About Mary Kay

One of the original glass ceiling breakers, Mary Kay Ash founded her beauty company more than 56 years ago with three goals: develop rewarding opportunities for women, offer irresistible products, and make the world a better place. That dream has blossomed into a multibillion-dollar company with millions of independent sales force members in nearly 40 countries. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skin care, color cosmetics, nutritional supplements and fragrances. Mary Kay is committed to empowering women and their families by partnering with organizations from around the world, focusing on supporting cancer research, protecting survivors from domestic abuse, beautifying our communities, and encouraging children to follow their dreams. Mary Kay Ash’s original vision continues to shine—one lipstick at a time. Learn more at MaryKay.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Mary Kay Inc. Corporate Communications
marykay.com/newsroom
972.687.5332 or media@mkcorp.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Data to Be Highlighted in Four Rapid Oral Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 Support Efforts to Improve Outcomes in Difficult-to-Treat Cancers17.7.2026 20:10:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced that it will highlight data from several programs in its oncology portfolio in six presentations at the European Society of Medical Oncology (ESMO) Congress 2026, being held October 23 - 27, 2026, in Madrid. “The data at ESMO will further illustrate Incyte’s commitment to advancing innovation for patients with cancer,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "Among the presentations are important updates from our KRAS G12D inhibitor in advanced pancreatic cancer and colorectal cancer, our TGFβR2×PD-1 bispecific antibody in microsatellite stable colorectal cancer and our CDK2 inhibitor in recurrent epithelial ovarian cancer – investigational approaches that reflect our focus on areas where there is significant need for novel therapies." Details on key data presentations at ESMO include: Rapid Oral Presentations INCB161734 (KRAS G12D) Safety and Efficacy of Oral KRAS G12D Inhibitor INCB161734 as Mono

STL Expands Its Optical Connectivity Portfolio in the US with the CONCAT Solution17.7.2026 15:24:00 EEST | Press release

STL Optical Connectivity NA, LLC, (STLOC), a U.S. subsidiary of STL (Sterlite Technologies Ltd.) [NSE: STLTECH], a leading connectivity solutions provider for AI-ready digital infrastructure, today announced that it launched its new advanced FTTH solution, CONCAT, after successfully completing field trials on the networks of one of the largest telecom service providers in the United States. Following successful field validation, CONCAT is now available to digital infrastructure providers seeking faster fiber rollouts with reduced deployment complexity and labor. It enables up to 71% in labor cost savings by eliminating most field splicing through factory-assembled, pre-connectorized fiber segments that deliver plug-and-play installation. CONCAT simplifies fiber deployment by shifting critical fiber preparation and termination into a controlled manufacturing environment ensuring consistent quality, faster installation, and lower operational risk in the field. CONCAT solution is ideal fo

China's ~$900B Live-Commerce Market Now Approaches US E-Commerce Scale17.7.2026 13:30:00 EEST | Press release

The center of gravity in global retail has shifted East. The formats now driving the fastest growth in global retail (live shopping, social commerce, and delivery in minutes) were pioneered and scaled in Asia, and most Western consumers have yet to adopt them. According to NIQ (NYSE: NIQ), a leading consumer intelligence company, in its global report The Commerce Revolution: Where East Meets West, the gap between East and West is still vast. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260717253489/en/ China´s USD 900bn live shopping boom now approaches the scale of the US E-commerce The scale is already substantial. China's live-commerce market alone was worth roughly $900 billion in 2025, approaching the size of the entire US e-commerce market, according to market data cited in the report. Yet 68% of consumers in North America and 67% in Europe have never once bought a product through social media, and roughly two-thirds

Aqemia and Sanofi Expand Their Research Collaboration17.7.2026 13:30:00 EEST | Press release

Aqemia, the drug invention company combining generative AI and quantum-inspired physics to invent small molecule drugs, today announced the expansion of its multi-year research collaboration with the global pharmaceutical company, Sanofi. The expansion is marked by the nomination of a new therapeutic target and an additional payment. The collaboration, first announced in December 2023, makes Aqemia eligible to receive up to a total of $140 million in upfront and milestone payments across programs. It spans the drug discovery journey from the identification of the very first hits to the selection of a development candidate. Aqemia leverages Qemi, its proprietary physics-based generative AI platform, to design novel molecules addressing Sanofi’s targets of choice, working in close collaboration with Sanofi scientific teams. Sanofi leads wet lab research, development and commercialization. The collaboration now runs across continents, between Aqemia researchers in Paris and London and San

Ant International’s Alipay+ Connects Argentina's National QR Payment Scheme via PVS, Enabling for Cross-Border Digital Payment Nationwide at Millions of Merchants17.7.2026 13:17:00 EEST | Press release

Alipay+, a global digital payment gateway under Ant International, today announced that it will enable global travellers to make QR code payments at millions of merchants across Argentina through integration with the country's national QR payment scheme Transferencias 3.0, in partnership with PVS, a fintech company specialized in developing customized payment solutions in Latin America. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260717276406/en/ By connecting to Argentina's national QR payment scheme, Alipay+ now enables global travellers in the country to make convenient QR code payments at merchants nationwide. This service helps to enhance global travellers' travel experiences in Argentina, allowing them to pay seamlessly at restaurants, malls and tourist attractions. Using an Alipay+ partner payment app, they can now scan the national QR code displayed at all merchants to make cross-border payments across Argentina,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye